2008
DOI: 10.1136/vr.162.8.241
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of 11 dogs with meningoencephalomyelitis of unknown origin with a combination of prednisolone and cytosine arabinoside

Abstract: The records of 11 dogs with evidence of meningoencephalomyelitis of unknown origin were reviewed. Two of them had had a focal form of the disease and the other nine a disseminated form. The forebrain was involved in five of the nine dogs with disseminated disease, the brainstem in all nine and the cerebellum in one. They had been treated with courses of cytosine arabinoside every three weeks and immunosuppressive doses of prednisolone. Their response to the treatment, in terms of quality of life, was judged by… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

7
53
0

Year Published

2009
2009
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 46 publications
(60 citation statements)
references
References 28 publications
7
53
0
Order By: Relevance
“…The above findings were compatible with the diagnosis of MUO (Schatzberg 2005, Schatzberg and others 2005, Zarfoss and others 2006, Menaut and others 2008) considering the multifocal lesions noticed on MRI and the CSF results. Immunosuppressive treatment was initiated with prednisolone (Prednicare; Animalcare) and cytosine arabinoside (Cytarabine 20 mg/ml injection; Mayne Pharma) (Scott-Moncrieff and others 1991, Cuddon and others 2002, Nuhsbaum 2002, Zarfoss and others 2006).…”
supporting
confidence: 87%
“…The above findings were compatible with the diagnosis of MUO (Schatzberg 2005, Schatzberg and others 2005, Zarfoss and others 2006, Menaut and others 2008) considering the multifocal lesions noticed on MRI and the CSF results. Immunosuppressive treatment was initiated with prednisolone (Prednicare; Animalcare) and cytosine arabinoside (Cytarabine 20 mg/ml injection; Mayne Pharma) (Scott-Moncrieff and others 1991, Cuddon and others 2002, Nuhsbaum 2002, Zarfoss and others 2006).…”
supporting
confidence: 87%
“…Hematologic abnormalities included thrombocytosis (n = 25 dogs), elevated liver enzyme activities (17), hypertriglyceridemia (13), elevated lipase or amylase activity (5), anemia (3), leukopenia (3), hypercalcemia (3), and hypocalcemia (2). Relevant hematologic abnormalities were infrequent.…”
Section: Resultsmentioning
confidence: 99%
“…144 Selection of a specific immunosuppressive protocol depends on the clinician's decision, the patient's clinical status, and the pet owner's financial considerations. In accordance with guidelines from other studies, 17,147,148,151 a common protocol is daily administration of prednisone at an immunosuppressive dose combined with cytosine arabinoside administered at 50 mg/m 2 every 12 hours as a subcutaneous bolus for 2 consecutive days, or by intravenous infusion at 200 mg/m 2 over 8 hours. The treatment cycle is repeated every 3 to 4 weeks for 3 cycles.…”
Section: Treatmentmentioning
confidence: 87%
“…Reported second-line immunosuppressive drug therapies for MUO include leflunomide, 145 procarbazine, 146 cytosine arabinoside, 17,[147][148][149][150][151][152] lomustine, 144,153 mycophenolate mofetil, 154 azathioprine 155 ; COP 149 (cyclophosphamide, vincristine, prednisone), and cyclosporine ( Table 3). 118,[155][156][157][158][159] Radiation therapy has also proved to be effective for focal GME lesions.…”
Section: Treatmentmentioning
confidence: 99%
See 1 more Smart Citation